[1]
|
Alzheimer’s Disease Facts and Figures, 2007. A Statistical Abstract of US Data on Alzheimer’s Disease published by the Alzheimer’s Association.
http://www.alz.org/national/documents/Report_2007FactsAndFigures.pdf
|
[2]
|
Alzheimer’s Disease Facts and Figures, Alzheimer’s Association, 2010.
http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf
|
[3]
|
Generation Alzheimer’s: The Defining Disease of the Baby Boomers.
http://act.alz.org/site/DocServer/ALZBoomersReport.pdf?docID=521
|
[4]
|
Alzheimer’s Disease Facts and Figures, 2011.
http://www.alz.org/downloads/Facts_Figures_2011.pdf
|
[5]
|
R. Altman and J. C. Rutledge, “The Vascular Contribution to Alzheimer’s Disease,” Clinical Science, Vol. 119, 2010, pp. 407-421. doi:10.1042/CS20100094
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950620/?tool=pubmed
|
[6]
|
R. A. Sperling, P. S. Aisen, L. A. Beckett, et al., “Toward Defining the Preclinical Stages of Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease,” Journal of Alzheimer’s & Dementia, Vol. 7, No. 3, 2011, pp. 280-292.
http://www.alzheimersanddementia.com/article/S1552-5260(11)00099-9/abstract
|
[7]
|
A. Fagan, C. Xiong, R. Bateman, et al., “Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer’s Disease,” Journal of Alzheimer’s & Dementia, Vol. 7, No. 4, 2011, p. 287.
http://www.alzheimersanddementia.com/article/S1552-5260(11)00972-1/fulltext
|
[8]
|
R. J. Perrin, R. Craig-Schapiro, J. C. Morris, et al., “Identification and Validation of Novelcerebrospinal Fluid Biomarkers for Staging Early Alzheimer’s Disease,” Public Library of Science One, Vol. 12, No. 6, 2011, p. e16032.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020224/?tool=pmcentrez
|
[9]
|
B. C. Dickerson, “Functional Magnetic Resonance Imaging of Cholinergic Modulation in Mild Cognitive Impairment,” Current Opinion in Psychiatry, Vol. 19, 2006, pp. 299-306. doi:10.1097/01.yco.0000218602.25346.c6
http://www.nmr.mgh.harvard.edu/~bradd/dickerson_curropnpsych_2006.pdf
|
[10]
|
A. J. Saykin, H. A. Wishart, L. A. Rabin, et al., “Older Adults with Cognitive Complaints Show Brain Atrophy Similar to That of Amnestic MCI,” Neurology, Vol. 67, 2006, pp. 834-842.
doi:10.1212/01.wnl.0000234032.77541.a2
http://www.neurology.org/cgi/content/abstract/67/5/834
|
[11]
|
W. S. Tae, S. S Kim, K. U. Lee, et al., “Validation of Hippocampal Volumes Measured Usinga a Manual Method and Two Automated Methods (Free Surfer and IBASPM) in Chronic Major Depressive Disorder,” Neuroradiology, Vol. 50, 2008, pp. 569-581.
doi:10.1007/s00234-008-0383-9
http://www.ncbi.nlm.nih.gov/pubmed/18414838
|
[12]
|
I. V. Maksimovich, L. N. Gotman and S. M. Masyuk, “Method of Determining Dimensions of Temporal Brain Lobes in Patients Suffering from Alzheimer’s Disease,” Russian Patent, No 2306102, 2006.
http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20070920&CC=RU&NR=2306102C1&KC=C1
|
[13]
|
S. L. Risacher, A. J. Saykin, J. D. West, et al., “Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort,” Current Alzheimer Research, Vol. 6, No. 4, 2009, pp. 347-361.
doi:10.2174/156720509788929273
http://www.bentham.org/car/openaccssearticles/car6-4/0007.pdf
|
[14]
|
L. Shen, H. A. Firpi, A. J. Saykin, et al., “Parametric Surface Modeling and Registration for Comparison of Manual and Automated Segmentation of the Hippocampus,” Hippocampus, Vol. 19, No. 6, 2009, pp. 588-595.
doi:10.1002/hipo.20613
http://picsl.upenn.edu/caph08/papers/paper07.pdf
|
[15]
|
G. Waldemar, B. Dubois, M. Emre, et al., “Recommendations for the Diagnosis and Management of Alzheimer’s Disease and Other Disorders Associated with Dementia: EFNS Guideline,” European Journal of Neurology, Vol. 14, No. 1, 2007, pp. e1-e26.
doi:10.1111/j.1468-1331.2006.01605.x
http://www.ncbi.nlm.nih.gov/pubmed/17222085
|
[16]
|
I. V. Maksimovich, “Possibilities of Modern Computed Tomography of Brain in Alzheimer’s Disease Diagnosis,” The Neurologic Bulletin, Vol. XLI, No. 1, 2009, pp. 5-10.
http://www.infamed.com/nb/1_2009_5-10.pdf
|
[17]
|
S. Adriaase, E. Sanz-Arigita, M. Binnewijzend, et al., “Molecular Markers of Alzheimer’s Disease Pathology and Their Relationship with Default Mode Network Integrity,” Alzheimer’s & Dementia, Vol. 7, No. 4, 2011, pp. S2-S3. doi:10.1016/j.jalz.2011.05.005
http://www.alzheimersanddementia.com/article/S1552-5260(11)00144-0/fulltext
|
[18]
|
C. Jack, P. Vemuri, H. Viste, et al., “Ordering of Alzheimer’s Disease Biomarkers,” Alzheimer’s & Dementia, Vol. 7, No. 4, 2011, pp. S4-S5.
doi:10.1016/j.jalz.2011.05.011
http://www.alzheimersanddementia.com/article/S1552-5260(11)00150-6/images
|
[19]
|
J. Q. Trojanowski, H. Vandeerstichele, M. Korecka, et al., “Update on the Biomarker Core of the Alzheimer’s Disease Neuroimaging Initiative Subjects,” Alzheimer’s & Dementia, Vol. 6, No. 3, 2010, pp. 230-238.
doi:10.1016/j.jalz.2010.03.008
http://www.ncbi.nlm.nih.gov/pubmed/20451871
|
[20]
|
P.T. Meyer, S. Hellwig, F. Amtage, et al., “Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B,” Journal of Nuclear Medicine, Vol. 52, No. 3, 2011, pp. 393-400.
doi:10.2967/jnumed.110.083683
http://www.ncbi.nlm.nih.gov/pubmed/21321269
|
[21]
|
F. Morel “An Apparently Dyshoric and Topical Angiopathy,” Monatsschrift für Psychiatrie und Neurologie, Vol. 120, No. 5-6, 1950, pp. 352-357.
doi:10.1159/000140150
http://www.ncbi.nlm.nih.gov/pubmed/14806299
|
[22]
|
I. Skoog, R. N. Kalaria and M. M. Breteler, “Vascular Factors and Alzheimer Disease,” Alzheimer Disease and Associated Disorders, Vol. 13, No. 3, 1999, pp. 106-114.
doi:10.1097/00002093-199912003-00016
http://www.ncbi.nlm.nih.gov/pubmed?term=Skoog%20I%2C%20Kalaria%20R%20N%2C%20Breteler%20M.M.
|
[23]
|
R. N. Kalaria, “Small Vessel Disease and Alzheimer’s Dementia: Pathological Considerations,” Cerebrovascular Diseases, Vol. 13 No. 2, 2002, pp. 48-52.
doi:10.1159/000049150
http://www.ncbi.nlm.nih.gov/pubmed/11901243
|
[24]
|
R. N. Kalaria, “Vascular Factors in Alzheimer’s Disease,” International Psychogeriatric, Vol. 15, No. 1, 2003, pp. 47-52. doi:10.1017/S1041610203008950
http://www.ncbi.nlm.nih.gov/pubmed/16191216
|
[25]
|
I. V. Maksimovich, “Changes in Angioarchetectonics of Brain at Alzheimer’s Disease,” The Neurological Bulletin, Vol. XLI, No. 2, 2009, pp. 9-14.
http://www.infamed.com/nb/2_2009_9-14.pdf
|
[26]
|
P. A. Yates, R. Sirisriro, V. L. Villemagne, et al., “Cerebral Microhemorrhage and Brain {beta}-amyloid in Aging and Alzheimer’s Disease,” Neurology, Vol. 77, No. 1, 2011, pp. 48-54.
doi:10.1212/WNL.0b013e318221ad36
http://www.ncbi.nlm.nih.gov/pubmed/21700585
|
[27]
|
I. V. Maksimovich, “Radiodiagnostics of Alzheimer’s disease,” Diagnostics and Intervention Radiology, Vol. 2, No. 4, 2008, pp. 27-38.
http://www.radiology-di.ru/articles/155/126/tom-2-N4-2008.html
|
[28]
|
G. Rodriguez, P. Vitali, P. Calvini, C. Bordoni, N. Girtler, G. Taddei, G. Mariani and F. Nobili, “Hippocampal Perfusion in Mild Alzheimer’s Disease,” Psychiatry Research, Vol. 100, No. 2, 2000, pp. 65-74.
doi:10.1016/S0925-4927(00)00071-8
http://www.ncbi.nlm.nih.gov/pubmed/11114492
|
[29]
|
W. Chen, X. Song, S. Beyea, R. D’Arcy, Y. Zhan and K. Rockwood, “Advances in Perfusion Magnetic Resonance Imaging in Alzheimer’s Disease,” Journal of Alzheimer’s & Dementia, Vol. 7, No. 2, 2011, pp. 185-196.
http://www.alzheimersanddementia.com/article/S1552-5260(10)00105-6/abstract
|
[30]
|
R. O. Weller, M. Subash, S. D. Preston, I. Mazanti and R. O. Carare, “Perivascular Drainage of Amyloid-beta Peptides from the Brain and Its Failure in Cerebral Amyloid Angiopathy and Alzheimer’s Disease,” Brain Pathology, Vol. 18, No. 2, 2008, pp. 253-266.
doi:10.1111/j.1750-3639.2008.00133.x
http://www.ncbi.nlm.nih.gov/pubmed/18363936
|
[31]
|
A. Pezzini, E. Del Zotto, I. Volonghi, A. Giossi, P. Costa and A. Padovani, “Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage,” Current Medicinal Chemistry, Vol. 16, No. 20, 2009, pp. 2498-2513.
doi:10.2174/092986709788682047
http://www.ncbi.nlm.nih.gov/pubmed/19601795
|
[32]
|
Y. A. Chung, O. J. Hyun, J. Y. Kim, K. J. Kim and K. J. Ahn, “Hypoperfusion and Ischemia in Cerebral Amyloid Angiopathy Documented by 99mTc-ECD Brain Perfusion SPECT,” Journal of Nuclear Medicine, Vol. 50, No. 12, 2009, pp. 1969-1974. doi:10.2967/jnumed.109.062315
http://www.ncbi.nlm.nih.gov/pubmed/19910418
|
[33]
|
R. O. Weller, S. D. Preston, M. Subash and R. O. Carare, “Cerebral Amyloid Angiopathy in the Aetiology and Immunotherapy of Alzheimer’s Disease,” Alzheimer’s Research & Therapy, Vol. 1, No. 2, 2009, pp. 6-13.
http://www.ncbi.nlm.nih.gov/pubmed/19822028
|
[34]
|
I. V. Maksimovich and L. N. Gotman, “Method of Complex Radiation Diagnostics at Pre-clinical and Clinical Stages of Alzheimer’s Disease,” Russian Patent, No. 2315559, 2006. http://bankpatentov.ru/node/28577
|
[35]
|
I. V. Maksimovich, “Dyscirculatory Angiopathy of the Brain of Alzheimer’s Type,” Journal of Alzheimer’s & Dementia, Vol. 6, No. 4, 2010, pp. e34-e35.
http://www.alzheimersanddementia.com/article/S1552-5260(10)02300-9/fulltext
|
[36]
|
I. V. Maksimovich, “Dyscirculatory Angiopathy of Alzheimer’s Type,” Journal of Behavioral and Brain Science, Vol. 1, No. 2, 2011, pp. 57-68.
doi:10.4236/jbbs.2011.12008
http://www.scirp.org/journal/PaperInformation.aspx?paperID=4630
|
[37]
|
D. Wilkinson, “Drugs for Treatment of Alzheimers’ Disease,” International Journal of Clinical Practice, Vol. 55. No. 2, 2001, pp. 129-134.
http://www.ncbi.nlm.nih.gov/pubmed/11321852
|
[38]
|
S. Burgmans, M. P. Van Boxtel, E. F. Vuurman, F. Smeets, E. H. Gronenschild, H. B. Uylings and J. Jolles, “The Prevalence of Cortical Gray Matter Atrophy May Be Overestimated In the Healthy Aging Brain,” Neuropsychology, Vol. 23, No. 5, 2009, pp. 541-550.
doi:10.1037/a0016161
http://www.ncbi.nlm.nih.gov/pubmed/19702408
|
[39]
|
G. C. Chiang, Ph. S. Insel, D. Tosun, N. Schuff, D. Truran-Sacrey, S. Raptentsetsang, C. R. Jack and M. W. Weiner, “Identifying Cognitively Healthy Elderly Individuals with Subsequent Memory Decline by using Automated MR Temporoparietal Volumes,” Radiology, Vol. 259, No. 3, 2011, pp. 844-851. doi:10.1148/radiol.11101637
http://www.ncbi.nlm.nih.gov/pubmed/21467255
|
[40]
|
J. C. Morris, “The Clinical Dementia Rating (CDR): Current Version and Scoring Rules,” Neurology, Vol. 11, No. 43, 1993, pp. 2412-2414.
http://www.neurology.org/content/43/11/2412.2.full.pdf+html
|
[41]
|
I. V. Maksimovich, “Method for Endovascular Treatment of Alzheimer’s Disease,” Russian Patent, No. 2297860, 2006.
http://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20070427&DB=EPODOC& locale=en_EP&CC=RU&NR=2297860C1&KC=C1
|
[42]
|
I. V. Maksimovich, “Method and Device for Endovascular Treatment of Alzheimer’s Disease,” Patent US, No. 7389776, 2008.
http://www.freepatentsonline.com/7389776.pdf
|
[43]
|
I. V. Maksimovich, “Endovascular Procedures in Treatment of the Alzheimer’s Disease,” Journal Diagnostic and Intervention Radiology, Vol. 3, No. 2, 2009, pp. 23-35.
http://www.radiology-di.ru/articles/158/177/tom-3-N2-2009.html
|
[44]
|
I. V. Maksimovich, “Endovascular Low-Energy Laser Radiation Effect on Dyscirculatory Angiopathy of Alzheimer’s Type in the Treatment of Alzheimer’s Disease,” Journal of Alzheimer’s & Dementia, Vol. 7, No. 4, 2011, pp. S791-S793.
http://www.alzheimersanddementia.com/article/S1552-5260(11)02427-7/fulltext
|
[45]
|
A. Venneri, M. F. Shanks, R. T. Staff, et al., “Cerebral Blood Flow and Cognitive Responses to Rivastigmine Treatment in Alzheimer’s Disease,” Neuroreport, Vol. 13, No. 1, 2002, pp. 83-87. .
doi:10.1097/00001756-200201210-00020
http://www.ncbi.nlm.nih.gov/pubmed/11924899
|
[46]
|
A. Fredriksson, W. Danysz, G. Quack, et al., “Coadministration of Memantine and Amantadine with Sub/supratheshold Doses of L-Dopa Restores Motor Behaviour of MPTP-Treated Mice,” Journal of Neural Transmission, Vol. 108, No. 2, 2001, pp. 167-187.
doi:10.1007/s007020170086
http://www.ncbi.nlm.nih.gov/pubmed?term=Fredriksson%20A%2C%20Danysz%20W%2C%20Quack%20G%2C%20et%20al
|
[47]
|
D. Wilkinson, “Drugs for Treatment of Alzheimer’s Disease,” International Journal of Clinical Practice, Vol. 55, No. 2, 2001, pp. 129-134.
http://www.ncbi.nlm.nih.gov/pubmed/11321852
|
[48]
|
I. V. Maksimovich, “Transljuminal Laser Angioplasty in Treatment of Ischemic Lesions of a Brain,” M.D. Dissertation, Russian University of Friendship of the People, Moscow, 2004.
http://disseng.com/page/order/id/206426.html
|
[49]
|
G. K. Chizhov, N. I. Koval’skaia and V. I. Kozlov, “The Effect of Helium-Neon Laser Radiation on the Energy Metabolic Indices of the Myocardium,” Biulleten’ Eksperimental’no? Biologii i Meditsiny, Vol. 111, No. 3, 1991, pp. 302-305.
http://www.ncbi.nlm.nih.gov/pubmed/2054512
|
[50]
|
V. I. Kozlov and G. A. Aziziv, “Pathophysiological Characteristics of Microcirculatory Disorders in Chronic Arterial Ischaemia of Lower Limbs,” Angiology and Vascular Surgery, Vol. 13, No. 7, 2007, pp. 17-23.
http://www.ncbi.nlm.nih.gov/pubmed/17679971
|
[51]
|
S. V. Moskvin, “System Analysis of Efficiency in Controlling Biological Systems with Low-Energy Laser Radiation,” Thesis for Degree of Doctor of Biological Sciences, City of Tula, 2008.
http://www.dissers.info/disser_323120.html
|
[52]
|
Ch. Heinrich, R. Blum, S. Gascón, et al., “Directing Astroglia from the Cerebral Cortex into Subtype Specific Functional Neurons,” PLoS Biology, Vol. 8, No. 5, 2010, p. e1000373. doi:10.1371/journal.pbio.1000373
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872647/?tool=pmcentrez
|